PHGDH and osteosarcoma: Furthermore, medium to high levels of PHGDH were associated with decreased relapse-free survival (median relapse-free survival [RFS] 1.25 years [low] versus >15 years [not reached; medium/high]) (hazard ratio [HR] 1.93 [range 1.20–3.10], p = 0.006; Figure 1E) and decreased overall survival (OS; median OS 4.6 years [low] versus >15 years [not reached; medium/high]) (HR 1.86 [range 1.11–3.10], p = 0.018; Figure 1F) in resection samples from patients with osteosarcoma and localized disease who received neoadjuvant chemotherapy.